Malin Corporation (MLC.IR) Osake Kurssi
Malin Corporation Kurssi
Viimeisten 5 vuoden aikana Malin Corporationn liikevaihto kasvoi 12,4 % vuodessa ja ylsi 41,00 M EUR:een. Osakekohtainen tulos on laskenut 38,2 % vuodessa viimeisten 2 vuoden aikana. Malin Corporationn nettomarginaali 213,9 % on noussut verrattuna −198,3 %:iin muutama vuosi sitten. Malin Corporationn 12 kuukauden konsensustavoitehinta on 15,81 EUR, noin yli kurssia 125,9 %. 5 analyytikosta 4 suosittaa ostoa — kokonaiskonsensus on Osta. Osake noteerataan noin 3 % 52 viikon pohjan yläpuolella.
Malin Corporation osakekurssi
Malin Corporation liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Malin Corporation -osakkeesta
The business model of Malin Corporation PLC is focused on strategic investments in life sciences companies with significant growth potential. Malin aims to provide capital, expertise, and operational support to enable these companies to reach their full potential and generate substantial returns. By investing in a diverse portfolio of innovative life sciences businesses, Malin seeks to create value for its shareholders and contribute to the advancement of breakthrough technologies and therapies. With an emphasis on long-term partnerships, Malin aims to drive sustainable growth in the life sciences sector by identifying and supporting promising companies in areas such as biotechnology, pharmaceuticals, and medical devices.
Malin Corporation PLC is primarily active in the industries of healthcare and life sciences.
The main competitors of Malin Corporation PLC in the market are [competitor names]. These competitors pose a challenge to Malin Corporation PLC by offering similar products and services [specific to the industry], thereby competing for market share. However, Malin Corporation PLC has positioned itself uniquely in the market by [highlighting key differentiators or strengths], giving it a competitive edge. Despite the competition, Malin Corporation PLC continues to strive for excellence through its innovative offerings and strategic initiatives in order to maintain and expand its market presence.
Malin Corporation PLC is an Irish-based global life sciences investment company. Founded in 2015, its primary focus is on creating long-term shareholder value through strategic investments in innovative companies. Malin seeks to partner with businesses across various life sciences sectors, including biotechnology, therapeutics, medical devices, and diagnostics. With a goal to support the development of breakthrough technologies, Malin engages in active collaboration and provides financial and strategic support to its investee companies. While continually expanding its portfolio, Malin maintains a strong commitment to driving advances in healthcare and delivering value to its shareholders.
Malin Corporation PLC has achieved several significant milestones. Firstly, the company successfully completed its initial public offering (IPO) on the Irish Stock Exchange in 2015, raising substantial funds for its investment portfolio. In 2016, Malin Corporation acquired a strategic stake in Poseida Therapeutics, an innovative gene engineering company. The company further expanded its portfolio by investing in promising life science companies like Immunocore, Kymab, and Serenus Biotherapeutics. In 2019, Malin Corporation celebrated the FDA approval of its investee company, Outpost Medicine's drug, for the treatment of overactive bladder. These achievements demonstrate Malin Corporation PLC's commitment to investing in breakthrough medical technologies and its potential for long-term growth.
Malin Corporation PLC primarily operates in Ireland.
Malin Corporation PLC represents a strong set of values and a well-defined corporate philosophy. The company is dedicated to delivering long-term shareholder value through strategic investments in innovative life sciences companies. Malin Corporation aims to support diverse and forward-thinking businesses that have the potential to positively impact global health. By fostering growth and nurturing breakthrough technologies, Malin Corporation PLC promotes collaboration and excellence within the life sciences industry. With a steadfast commitment to ethical practices and responsible investments, Malin Corporation PLC strives to enhance patient outcomes and contribute to the advancement of healthcare worldwide.
Analyytikot asettavat tällä hetkellä Malin Corporation-osakkeelle keskimääräisen tavoitehinnan 15,81 EUR (mediaani: 15,81 EUR), mikä merkitsee +125,9 % viimeisimpään hintaan verrattuna. Konsensus perustuu 5 analyytikkoarvioon.
5 analyytikkoa arvioi tällä hetkellä Malin Corporation-osaketta: 4 suosittaa ostoa, 1 pitoa ja 0 myyntiä.
Malin Corporation PLC is an innovative Irish company specializing in investing in medical products. The company operates in various business areas, including the development and manufacture of pharmaceutical products, investment in innovative biotechnology startups, and the establishment of partnerships for scientific research projects. The manufacture of medical products is Malin's main business area. The company offers a wide range of products, ranging from drugs for rare diseases to antibiotics. The products are manufactured to the highest quality standards and are available to patients worldwide. An important part of Malin's business model is investing in innovative biotechnology startups. The company strives to find and support new technologies that contribute to improving human health. By collaborating with other companies and investors in the biotechnology field, Malin can advance innovative research and development that is of great benefit to its customers. Malin has also established partnerships for scientific research projects. Together with internationally leading research institutions and universities, the company is committed to the development of new drugs and therapies to meet the needs of patients. This collaboration aims to achieve scientific breakthroughs and find new treatment options for serious diseases. Overall, Malin's business model is focused on developing and providing innovative and effective drugs and therapies for patients. The company places special emphasis on adhering to high standards in research and production. By collaborating with other companies and research institutions, Malin achieves a broader base of knowledge, technology, and skills to remain competitive in the market. In summary, Malin Corporation PLC is an innovative company with a wide portfolio of medical products, investments in biotechnology startups, and research collaborations. With its focus on quality and innovation, Malin is a growing company that contributes to improving human health with its business model.
Liikevaihtoa ei voida laskea Malin Corporation:lle tällä hetkellä.
odotettu voitto Malin Corporation on −4,19 M EUR. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Malin Corporation:n hinta-voitto-suhde (P/E) on tällä hetkellä −31,66. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Malin Corporation-osakkeen arvostusta.
P/S-suhdetta ei voida laskea Malin Corporation:lle tällä hetkellä.
Malin Corporation:n Eulpool-laatuscore on 1/10.
Malin Corporation:n ISIN on IE00BVGC3741. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Malin Corporation:n ticker on MLC.IR. Tämä pörssinoteeraus käytetään Malin Corporation-osakkeiden kauppaan pörssissä.
Malin Corporation maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.
Malin Corporation kuuluu sektoriin 'Terveydenhuolto'.
Malin Corporation:n osingot jaetaan valuutassa EUR.
Malin Corporation osake
Malin Corporation vertaisryhmä
Malin Corporation FIGI
Kaikki tunnusluvut ja syvällinen analyysi Malin Corporation:sta
Meidän osakeanalyysimme Malin Corporation-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Malin Corporation:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: